Chemistry: molecular biology and microbiology – Vector – per se
Patent
1990-05-07
1993-01-12
Wax, Robert A.
Chemistry: molecular biology and microbiology
Vector, per se
435208, 4352401, 536 232, 935 23, 935 32, 935 70, C12N 1500, C12N 940, C12N 1506, C12N 1586
Patent
active
051790238
ABSTRACT:
Fabry disease results from an X-linked deficiency in the enzyme .alpha.-galactosidase A. The present invention is directed to recombinant human .alpha.-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of .alpha.-galactosidase A are also provided.
REFERENCES:
Jennifer Van Brunt (1990) "The Importance of Glycoform Heterogeneity", Bio/Technology, 8, p. 995.
Davidson et al. (1990) "Oligosaccharide Processing in the Expression of Human Plasminogen cDNA by Lepidopteran Insect (Spodoptera frugiperda) Cells", Biochemistry, 29, 5584-5590.
Davidson et al. (1991) "Asparagine-Linked Oligosaccharide Processing in Lepid-opteran Insect Cells, Temporal Dependence of the Nature of the Oligosaccharides Assembled on Asparagine-289 of Recombinant Human Plasminogen Produced in Baculovirus Vector Infected Spodoptera frugipenda (IPIB-SF-21AE) Cells", Biochemistry, 30, 6167-6174.
Davidson et al. (1991) "Oligosaccharide Structures Present on Asparagine-289 of Recombinant Human Plasminogen Expressed in a Chinese Hamster Ovary Cell Line", Biochemistry, 30, 625-633.
Bishop et al. (1981) "Affinity Purification of .alpha.-Galactosidase A from Human Spleen, Placenta and Plasma with Elimination of Pyrogen Contamination", The Journal of Biological Chemistry, 256, 1307-1316.
Desnick et al. (1979) "Enzyme Therapy in Fabry Disease: Differential in vivo Plasma Clearance and Metabolic Effectiveness of Plasma and Splenic .alpha.-Galactosidase A Isozymes" Proc. Natl. Acad. Sci. USA, 76, 5326-5330.
Goochee et al. (1990) "Environmental Effects on Protein Glycosylation", Bio/Technology, 8, 421-427.
Greenfield et al. (1988) "Expression of the Human EGF Receptor with Ligand-Stimulatable Kinase Activity in Insect Cells using a Baculovirus Vector", The EMBO Journal, 7, 139-146.
Goto et al. (1988) "Production of Recombinant Human Erythropoietin in Mammalian Cells: Host-Cell Dependency of the Biological Activity of the Cloned Glycoprotein", Bio/Technology, 6, 67-71.
Miller (1988) "Vaculoviruses as Gene Expression Vectors", Ann. Rev. Microbiol., 42, 177-199.
Rademacher et al. (1988) "Glycobiology", Ann. Rev. Biochem., 57, 785-838.
Sheares et al. (1986) "Glycosylation of Ovalbumin in a Hetereologous Cell: Analysis of Oligosaccharide Chains of the Cloned Glycoprotein in Mouse L Cells", Proc. Natl. Acad. Sci. USA, 83, 1993-1997.
Wojchowski et al. (1987) "Active Human Erythropoietin Expressed in Insect Cells using a Baculovirus Vector: A Role for N-Linked Oligosaccharide", Biochimica et Biophysica Acta, 910, 224-232.
Bishop et al. (1986) Proc. Natl. Acad. Sci. USA 83: 4859-4863.
Calhoun et al. (1985) Proc. Natl. Acad. Sci. USA 82; 7364-7368.
Hantzoupoulos et al. (1987) Gene 57: 159-169.
Luckow et al. (1988) Bio/Technology 6: 47-55.
Quinn et al. (1987) Gene 58: 177-188.
Smith et al. (1983) Mol. Cell. Biol. 3: 2156-2165.
Tsuji et al. (1987) Eur. J. Biochem. 165: 275-280.
Calhoun David H.
Coppola George
Cook Dian
Research Corporation Technologies Inc.
Wax Robert A.
LandOfFree
Recombinant .alpha.-galactosidase a therapy for Fabry disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant .alpha.-galactosidase a therapy for Fabry disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant .alpha.-galactosidase a therapy for Fabry disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1219708